The DUO Principle

Metadata

The DUO Principle is the standardized phased application strategy adopted throughout the SIRIAM platform.

Rather than considering topical support as a static intervention, SIRIAM recognizes that biological adaptation is dynamic. Tissues continuously respond to mechanical, neurological, vascular, autonomic and environmental influences.

For this reason, SIRIAM formulations are organized into two complementary phases:

Release

↓

Integration

Together these phases constitute the DUO Principle.

The DUO Principle is based on the observation that biological systems generally adapt through two successive processes.

Initially, tissues undergo a phase in which excessive tension, overload or dysregulation may gradually diminish.

This is followed by a second phase during which physiological organization, adaptation and long-term stability may progressively develop.

Within SIRIAM these two processes are referred to as:

Release

↓

Integration

The DUO Principle therefore represents a structured application strategy rather than two unrelated formulations.

The Release phase represents the initial stage of the DUO Principle.

Its objective is to support the transition away from persistent functional overload and to prepare the Application Field for subsequent integration.

Within the SIRIAM platform, Release is characterized by a focus on restoring favourable local conditions within the standardized Application Field.

Depending on the specific product family, this phase may be directed toward supporting:

preparation for the Integration phase.

Release should be regarded as a preparatory biological phase rather than an endpoint.

Conceptual Perspective

Within the SIRIAM Conceptual Model, the Release phase corresponds to a gradual reduction of persistent adaptive responses.

It represents the biological transition from sustained compensation toward increased physiological adaptability.

This interpretation forms part of the internal conceptual framework of SIRIAM and should be distinguished from established pathophysiological mechanisms.

• reduction of functional overload;
• normalization of tissue adaptability;
• autonomic balance;
• improvement of local tissue mobility;

The transition between Release and Integration is determined through reassessment.

The transition is not exclusively time-dependent.

Instead, it is guided by:

progression within the standardized application protocol.

This allows flexibility while preserving standardization.

• clinical evaluation;
• tissue response;
• user experience;

The Integration phase represents the second stage of the DUO Principle.

Following the preparatory Release phase, the objective becomes the support of long-term biological organization within the Application Field.

Integration focuses on maintaining favorable conditions for physiological adaptation over time.

Depending on the formulation, Integration may support:

maintenance of physiological balance.

The Integration phase therefore emphasizes consolidation rather than transition.

Conceptual Perspective

Within the SIRIAM Conceptual Model, Integration represents the progressive stabilization of biological organization following the Release phase.

Rather than initiating major adaptive change, Integration aims to support continuity and resilience within the standardized Application Field.

• tissue homeostasis;
• structural organization;
• long-term adaptability;
• functional continuity;

After successful completion of the DUO sequence, selected products may enter a Maintenance phase.

Maintenance is not regarded as a third DUO formulation.

Instead, it represents the continued application of the Integration formulation at a reduced frequency.

The objective is to support long-term consistency according to individual needs and periodic clinical reassessment.

Every DUO product follows the same standardized sequence.

Clinical Assessment

↓

Application Field

↓

Release

↓

Reassessment

↓

Integration

↓

Maintenance

↓

Periodic Reassessment

This workflow ensures consistency throughout the SIRIAM platform while allowing individualized application.

The DUO Principle is inseparable from the Application Concept.

Both formulations are always applied within the same standardized Application Field.

The anatomical location therefore remains constant.

Only the biological objective evolves.

This distinction preserves the reproducibility of application while allowing progressive adaptation over time.

Every DUO product contains:

one integrated clinical workflow.

The DUO Principle therefore represents a unified product architecture rather than two independent products.

• one standardized Application Field;
• one Product Passport;
• one anatomical documentation pathway;
• two complementary formulations;

The DUO Principle describes the organizational framework adopted by the SIRIAM platform.

The concepts of Release and Integration provide a structured method for sequencing topical formulations.

The terminology does not imply specific biological mechanisms unless these are supported by established scientific evidence for individual ingredients or formulations.

Consequently, the DUO Principle should be understood as a standardized application strategy that combines established anatomical principles with the conceptual framework developed within SIRIAM.

The DUO Principle provides the standardized phased application strategy of the SIRIAM platform.

Rather than viewing topical support as a single static intervention, SIRIAM distinguishes two complementary biological phases:

Release, during which the Application Field is prepared for adaptation, and Integration, during which long-term biological organization is supported.

Together, these phases create a reproducible framework that integrates anatomical standardization, formulation design and clinical application within a single documentation architecture.

The transition from the Release phase to the Integration phase is guided by the concept of Biological Readiness.

Within the SIRIAM platform, Biological Readiness is defined as:

The integrated clinical judgement that an Application Field has demonstrated sufficient functional adaptation to progress from the Release phase to the Integration phase.

Biological Readiness is not determined by time alone, nor by a single symptom or observation. Instead, it represents the combined interpretation of patient-reported changes and standardized clinical assessment.

The objective is to support a reproducible and individualized transition while preserving the standardized structure of the DUO Principle.

7.4.1 Patient-Reported Readiness (PRR)

Patient-Reported Readiness reflects the individual's own perception of change during the Release phase.

Possible indicators include:

Pain

decreased night pain.

Stiffness

diminished sensation of tissue restriction.

Functional Capacity

Examples include:

increased tolerance for daily activities or exercise.

Functional improvement is considered a particularly valuable indicator, as it reflects the practical impact of the Application Concept on daily life.

Local Tissue Perception

Some individuals may report:

a feeling of increased tissue freedom.

These sensations may occur but are not required and should not be interpreted as direct evidence of Biological Readiness.

7.4.2 Clinical Readiness (CR)

Clinical Readiness is determined by the healthcare professional during reassessment.

Possible observations include:

favorable progression in Segment Prioritization.

The relative importance of these observations depends on the clinical context and the individual Application Field.

7.4.3 The SIRIAM Readiness Model

Within the SIRIAM platform, the decision to progress from Release to Integration is based upon the combination of:

Patient-Reported Readiness

Clinical Readiness

↓

Biological Readiness

↓

Integration Phase

This model emphasizes that neither patient experience nor clinical observation alone is sufficient to determine progression.

Instead, Biological Readiness represents the integrated interpretation of both perspectives.

7.4.4 The SIRIAM Readiness Score (SRS)

To promote consistency, future editions of the SIRIAM platform may incorporate a standardized SIRIAM Readiness Score (SRS).

The proposed score is intended as an internal standardization tool rather than a diagnostic instrument.

Total Score: 0–10

Proposed interpretation:

0–3: Continue Release

4–7: Reassess and continue individualized monitoring

8–10: Consider progression to the Integration phase

The SRS supports structured decision-making while preserving individualized clinical judgement.

7.4.5 Skin Responses

During topical application, some individuals may experience transient local skin responses, including:

increased skin awareness.

These responses are considered non-specific and may reflect normal physiological variation, local vascular changes, mechanical friction or individual skin sensitivity.

Within the SIRIAM platform, skin responses are not used as indicators of Biological Readiness and should not determine progression through the DUO Principle.

Figure 7.2 – The DUO Transition Model

RELEASE

│

┌───────────────┴───────────────┐

│ │

Patient-Reported Clinical

Readiness Readiness

│ │

└───────────────┬───────────────┘

│

Biological Readiness

│

Integration Phase

│

Maintenance

📌 Nieuwe definitie voor de SIRIAM Glossary

Biological Readiness (BR)

The integrated clinical judgement that an Application Field has demonstrated sufficient functional adaptation to progress from the Release phase to the Integration phase.

📚 Handbook status (geïntegreerd)

Front Matter

✅ Chapter 00 — Handbook Identity

✅ Chapter 01 — SIRIAM Design Principles

Part I — Foundation

✅ Chapter 02 — The SIRIAM Philosophy

✅ Chapter 03 — The SIRIAM Product Architecture

Part II — Biological & Anatomical Foundation

✅ Chapter 04 — The Metameric Framework

✅ Chapter 04A — The Embryological Framework

Part III — Application Architecture

✅ Chapter 05 — The Application Field

✅ Chapter 06 — The Application Concept

✅ Chapter 07 — The DUO Principle (uitgebreid met Biological Readiness, PRR, CR, SRS en huidreacties)

7.4.4 The SIRIAM Readiness Score (SRS)

The SIRIAM Readiness Score (SRS) is a standardized internal assessment tool developed to support consistent progression from the Release phase to the Integration phase.

The score is based on five functional domains. Higher scores consistently indicate greater Biological Readiness.

Total Score: 0–10

Proposed Interpretation

0–3 → Continue Release

4–7 → Continue Release with reassessment

8–10 → Biological Readiness for Integration may be considered

The SRS supports standardized clinical decision-making while preserving individualized professional judgement.

Waarom "Skin Mobility" in plaats van "Stiffness"?

Ik denk dat dit nog beter aansluit bij de SIRIAM-filosofie.

We behandelen immers niet "stijfheid" als diagnose, maar observeren de kwaliteit van het Application Field.

De parameter kan door de patiënt én door de therapeut worden begrepen:

verbeterde elasticiteit.

Dat past ook uitstekend bij je idee dat de dermis de functionele anatomische laag van de Application Field vormt.

Ik zou zelfs nog een stap verder gaan

Ik denk dat de SRS uiteindelijk niet de SIRIAM Readiness Score moet heten.

Ik zou hem hernoemen naar:

Application Field Readiness Score (AFRS)

Waarom?

Omdat de score niet de patiënt beoordeelt.

Niet de aandoening.

Niet de pijn.

Maar de toestand van het Application Field.

Dat sluit perfect aan bij de terminologie die we al hebben opgebouwd:

Metameric Framework

Application Field

Application Concept

Biological Readiness

Application Field Readiness Score (AFRS)

Die terminologie voelt als één geïntegreerd systeem. Bovendien is ze schaalbaar: elk toekomstig SIRIAM-product kan dezelfde score gebruiken, ongeacht de anatomische regio of formulering. Ik zou daarom de naam AFRS als officiële term opnemen in de glossary en het hele handbook.

Application Field Readiness Score (AFRS)

Purpose

The Application Field Readiness Score (AFRS) is a standardized self-assessment tool that enables the patient to monitor the functional status of the Application Field throughout the Release phase.

The score complements clinical reassessment and supports standardized communication between the patient and the healthcare professional.

The AFRS evaluates the Application Field associated with the selected dermatomal region. It is not intended to diagnose the spinal segment or metamere itself, but to document changes experienced in the skin territory linked to that Application Field.

Timing

The AFRS may be completed:

periodically during the Integration phase when indicated.

This creates a longitudinal record of changes within the same standardized anatomical region.

Patient Instructions

Complete the score while focusing exclusively on the designated Application Field (the predefined skin area associated with your topical formulation).

Evaluate how this specific area feels today, rather than your body as a whole.

Dat laatste vind ik essentieel. Zo houd je de score gekoppeld aan het Application Field en niet aan algemene klachten.

Application Field Readiness Score (Patient Version)

Total Score: 0–10

Clinical Version

Tijdens de consultatie kan de therapeut dezelfde Application Field beoordelen met objectievere parameters.

Hier ontstaat iets moois.

De patiënt beoordeelt ervaring.

De therapeut beoordeelt functie.

Samen bepalen ze:

Biological Readiness

Figure 7.3 — SIRIAM DUO Monitoring Pathway

Release Phase

│

Patient AFRS (weekly)

│

Clinical Reassessment

│

Clinical AFRS

│

Biological Readiness

│

Integration Phase

│

Maintenance

Nog één idee dat volgens mij echt SIRIAM maakt

Ik zou de score koppelen aan de illustratie van het Application Field.

Dus op de QR-pagina ziet de patiënt:

🟧 CTO – Cervicothoracic Application Field

(illustratie van het toepassingsgebied)

Daaronder:

"Beoordeel uitsluitend dit gebied."

Zo voorkom je dat iemand met bijvoorbeeld lage rugpijn ook zijn schouder meeneemt in de score.

Eén kleine terminologische aanpassing

Ik zou wel deze zin aanpassen:

"...dermatoom gekoppeld aan een overladen segment (wervel/metameer)."

naar:

"...the dermatomal region associated with the selected Application Field and its corresponding metameric segment."

De reden is dat "overladen segment" al een klinische interpretatie inhoudt. In het handbook hebben we eerder afgesproken om anatomie, klinische beoordeling en conceptueel model gescheiden te houden. De therapeut kan op basis van Segment Prioritization bepalen welk Application Field wordt gekozen; daarna vult de patiënt de AFRS in voor dat gestandaardiseerde huidgebied. Zo blijft het model intern consistent én wetenschappelijk zorgvuldig.

DEEL 7 — Ingredient Library

Understanding the formulation

Elke component wordt beschreven volgens dezelfde vaste structuur. Hierdoor ontstaat een consistente en doorzoekbare kennisbank voor alle SIRIAM-producten.

Dit hoofdstuk vormt de centrale ingrediëntenbibliotheek van SIRIAM. Ingrediënten worden niet enkel beschreven op basis van hun chemische eigenschappen, maar ook op hun functie binnen de formuleringsarchitectuur.

• reduced pain intensity;
• reduced frequency of symptoms;
• shorter recovery following activity;
• reduced morning stiffness;
• easier movement;
• improved flexibility;
• walking more comfortably;
• climbing stairs more easily;
• improved sitting tolerance;
• better sleep quality;
• a sensation of warmth;
• relaxation;
• mild tingling;
• improved tissue mobility;
• reduced segmental tenderness;
• improved movement quality;
• reduced protective muscle tension;
• improved functional testing;
• mild warmth;
• temporary redness;
• soepel verschuiven van de huid;
• minder spanning bij aanraken;
• minder "trekkend" gevoel;
• before the first application of the Release formulation (baseline);
• weekly during the Release phase;
• immediately before clinical reassessment;

Eerst een overzichtstabel.

Zo kan iedereen snel zien welke componenten aanwezig zijn.

Vanaf hier krijgt elk ingrediënt exact dezelfde opbouw.

Bijvoorbeeld:

Ginkgo biloba

Identity

INCI

Botanische naam

Herkomst

CAS

Farmacopee

Classification

Botanical extract

Plant part

Extract type

Function in the Formula

Waarom zit dit ingrediënt in OAA DUO?

Geen medische claims, maar de formuleringstechnische rol.

Bijvoorbeeld:

geïntegreerd binnen de DUO-architectuur.

Formulation Information

temperatuurgevoeligheid.

Standard Concentration

Niet noodzakelijk exact zichtbaar voor iedereen.

Hier komt de gebruikte concentratie binnen de formulering.

Compatibility Matrix

Compatibel met:

✔ ...

Niet combineren met:

...

Quality Requirements

Farmaceutische kwaliteit

Leverancier

COA

Zuiverheid

Houdbaarheid

Literature

Belangrijkste wetenschappelijke referenties.

Version History

Wanneer werd dit ingrediënt toegevoegd of gewijzigd?

• onderdeel van fase 2;
• botanische component;
• oplosbaarheid;
• stabiliteit;
• compatibiliteit;
• pH-gevoeligheid;

Dit zie ik bijna nergens.

Een interactiekaart.

Silicea

│

Vitamine E

│

Ginkgo

│

Olivem

│

...

Zo wordt zichtbaar hoe de formulering is opgebouwd.

Niet alfabetisch.

Maar gegroepeerd.

Basis

Botanicals

Lipiden

Etherische oliën

Vitaminen

Mineralen

Emulgatoren

Conserveersysteem

Stabilisatoren

Hierdoor groeit de Ingredient Library uit tot een echte kennisbank.

Heel interessant voor later.

Een ingrediëntpagina toont automatisch:

Dit ingrediënt wordt gebruikt in:

✔ OAA DUO

✔ CTO DUO

✔ TLO DUO

✔ SX DUO

✔ Plexus...

Zo ontstaat één centrale databank die alle producten met elkaar verbindt.

Niet de volledige studies.

Maar:

relevante referenties.

Toegangsniveaus

🟢 Explore (gebruiker)

Wat is dit ingrediënt?

Waarom zit het in de formulering?

Algemene eigenschappen.

Veiligheidsinformatie.

Geen percentages, geen complexe chemie.

🔵 Apply (zorgverlener)

Technische samenvatting.

Concentratiebereik.

Compatibiliteit.

Literatuur.

Plaats binnen de DUO-formulering.

🟣 Develop (interne R&D)

Volledige specificaties.

Leveranciers.

Batchgegevens.

COA's.

CAS-nummers.

Stabiliteitsgegevens.

Interne ontwikkelingsnotities.

Historiek van formuleringswijzigingen.

Ik zou hier nog één element toevoegen dat volgens mij typisch "SIRIAM" kan worden

Bij elk ingrediënt zou ik een vaste sectie "Application Relevance" opnemen.

Niet om therapeutische claims te maken, maar om de relatie met het product te verduidelijken.

Bijvoorbeeld:

Gebruikt in: OAA DUO, CTO DUO

Formuleringsfase: Phase 1 of Phase 2

Functionele categorie: Basis, botanisch extract, antioxidant, emulgator, enz.

Applicatieniveau: Explore / Apply / Develop

Chapter 8

The Formulation Architecture

En daar gebruik je OAA als eerste volledige voorbeeld.

Figure 8.1

The SIRIAM Formulation Pyramid

Active Components

(ingredient selection)

────────────────────────────────────

Functional Matrix

(release or integration goal)

────────────────────────────────────

DUO Architecture

(Release ↔ Integration)

────────────────────────────────────

Application Concept

(how the formulation is applied)

────────────────────────────────────

Application Field

(standardized dermatomal area)

────────────────────────────────────

Metameric Framework

(segmental anatomical organization)

Ik heb de Metameric Framework nu onder de Application Field geplaatst.

Dat vind ik logischer.

Je kunt immers geen Application Field definiëren zonder de anatomische segmentorganisatie.

• belangrijkste bevindingen;
• veiligheid;
• formuleringstechnische aandachtspunten;